9.76
price up icon3.06%   0.29
pre-market  Pre-market:  9.80   0.04   +0.41%
loading
Phathom Pharmaceuticals Inc stock is traded at $9.76, with a volume of 1.27M. It is up +3.06% in the last 24 hours and up +142.79% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$9.47
Open:
$9.59
24h Volume:
1.27M
Relative Volume:
0.48
Market Cap:
$626.23M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-1.8805
EPS:
-5.19
Net Cash Flow:
$-216.95M
1W Performance:
-7.05%
1M Performance:
+142.79%
6M Performance:
+30.13%
1Y Performance:
-9.88%
1-Day Range:
Value
$9.32
$10.11
1-Week Range:
Value
$8.86
$11.21
52-Week Range:
Value
$2.21
$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name
Name
Phathom Pharmaceuticals Inc
Name
Phone
(877) 742-8466
Name
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Name
Employee
427
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PHAT's Discussions on Twitter

Compare PHAT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PHAT
Phathom Pharmaceuticals Inc
9.76 626.23M 0 -297.11M -216.95M -5.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-25 Initiated Cantor Fitzgerald Overweight
May-03-24 Initiated Stifel Buy
Jan-05-24 Reiterated Needham Buy
Aug-09-23 Initiated H.C. Wainwright Buy
May-11-23 Upgrade Evercore ISI In-line → Outperform
Mar-13-23 Initiated Craig Hallum Buy
Oct-21-22 Initiated Jefferies Buy
May-06-22 Downgrade Evercore ISI Outperform → In-line
May-12-21 Upgrade Goldman Sell → Neutral
Feb-17-21 Initiated BMO Capital Markets Outperform
Feb-02-21 Initiated Guggenheim Buy
Jun-26-20 Downgrade Goldman Neutral → Sell
Nov-20-19 Initiated Evercore ISI Outperform
Nov-19-19 Initiated Goldman Neutral
Nov-19-19 Initiated Jefferies Buy
Nov-19-19 Initiated Needham Buy
View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

pulisher
Jun 17, 2025

FDA Approval for VOQUENZA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC - Quantisnow

Jun 17, 2025
pulisher
Jun 17, 2025

Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Phathom Pharmaceuticals Announces FDA Correction to Orange - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Phathom Pharmaceuticals' Heartburn Drug Receives Regulatory Exclusivity in FDA Orange Book Update - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Phathom Pharma: FDA Updates Orange Book To Reflect 10 Year NCE Regulatory Exclusivity For VOQUEZNA - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

Phathom Pharmaceuticals Announces FDA Correction to Orange Book - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Phathom Pharmaceuticals (PHAT) Secures Extended Exclusivity for VOQUEZNA | PHAT Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

FDA extends Phathom’s VOQUEZNA exclusivity period to 2032 By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

FDA Grants 10-Year Exclusivity for Breakthrough GERD Drug VOQUEZNA: Major Win for Phathom - Stock Titan

Jun 16, 2025
pulisher
Jun 11, 2025

Transcript : Phathom Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade - MSN

Jun 11, 2025
pulisher
Jun 10, 2025

Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy (PHAT) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 09, 2025

Phathom Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Phathom Pharmaceuticals (PHAT) Price Target Increased Following FDA Ruling | PHAT Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Phathom Pharmaceuticals (PHAT) Receives Buy Rating from HC Wainw - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long (NASDAQ:PHAT) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 09, 2025

Phathom Pharmaceuticals (PHAT) Analyst Rating Update: Price Target Raised to $17.00 | PHAT Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 07, 2025

Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald - MSN

Jun 07, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals (PHAT) Soars on FDA Approval and Market Exclusivity | PHAT Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals (PHAT) Soars Over 120% After FDA Update - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

FDA Grants Extended Exclusivity to Phathom Pharmaceuticals (PHAT - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

FDA Grants Phathom Pharmaceuticals (PHAT) Extended Exclusivity f - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals (PHAT) Surges 90% After FDA Grants 10-Year Exclusivity for Voquezna - Wealth Daily

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Gains FDA Approval for VOQUEZNA® Exclusivity - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals (PHAT) Receives Continued Buy Rating fro - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Gains Momentum with FDA Approval and Market Exclusivity for Voquezna - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Needham sees FDA’s positive CP ruling as best-case outcome for Phathom - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Rides High On FDA's Drug Approval - Finimize

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Soars 95% on FDA Exclusivity for VOQUEZNA - Wall Street Pit

Jun 06, 2025
pulisher
Jun 06, 2025

Guggenheim reiterates Buy on Phathom stock after FDA grants exclusivity - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Guggenheim reiterates Buy on Phathom stock after FDA grants exclusivity By Investing.com - Investing.com UK

Jun 06, 2025
pulisher
Jun 06, 2025

PHAT Stock Target Raised Amid Extended Drug Exclusivity | PHAT S - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock By Investing.com - Investing.com Canada

Jun 06, 2025
pulisher
Jun 06, 2025

Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

PHAT Stock Target Raised Amid Extended Drug Exclusivity | PHAT Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Stifel expects Phathom to ‘largely recover ground lost’ after FDA grants claim - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

PHAT Stock: Phathom Pharmaceuticals Stock Surges 128% as FDA Grants 10-Year Exclusivity for Voquezna - gondwanauniversity.org

Jun 06, 2025
pulisher
Jun 06, 2025

FDA Grants Extended Exclusivity to Phathom Pharmaceuticals (PHAT) | PHAT Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Says FDA Approves Co's Petition For 10 Years Exclusivity For Voquezna - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals (PHAT) Soars 125% on FDA Decision - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Announces Positive FDA Decision to Recog - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Shares Surge After FDA Grants 10-Year Exclusivity for Acid-Reducing Drug - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals (PHAT) Soars Over 120% After FDA Update | PHAT Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032 | PHAT Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom says FDA to correct Orange Book for Voquenza exclusivity - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory ... - Bluefield Daily Telegraph

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Announces Positive FDA Decision to - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for Vquezna®? Tablets Through May 3, 2032 - MarketScreener

Jun 06, 2025
pulisher
Jun 06, 2025

Phathom Pharmaceuticals shares soar on FDA exclusivity grant By Investing.com - Investing.com Nigeria

Jun 06, 2025

Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Topper James N
Director
May 14 '25
Buy
3.32
6,300
20,919
55,623
Topper James N
Director
May 13 '25
Buy
3.16
1,120
3,543
49,323
Topper James N
Director
May 09 '25
Buy
3.22
35,602
114,616
35,602
Topper James N
Director
May 12 '25
Buy
3.04
12,601
38,301
48,203
Parikh Asit
Director
May 06 '25
Buy
2.60
5,000
13,000
90,500
Parikh Asit
Director
May 07 '25
Buy
2.40
5,000
11,984
95,500
Henderson Molly
CFO and CBO
Apr 07 '25
Sale
4.55
3,678
16,740
89,868
Parikh Asit
Director
Sep 10 '24
Option Exercise
11.72
7,500
87,900
93,000
Parikh Asit
Director
Mar 13 '25
Buy
4.42
10,000
44,200
85,500
Henderson Molly
CFO and CBO
Jan 21 '25
Sale
6.59
6,583
43,371
93,546
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
Cap:     |  Volume (24h):